NasdaqCM - Delayed Quote USD

Alpha Tau Medical Ltd. (DRTSW)

0.2300

0.0000

(0.00%)

As of April 23 at 4:00:00 PM EDT. Market Open.

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology. “This is very exciting news for patients suffering from glioblastoma, a highly aggressive form of brain cancer wi

GlobeNewswire 22 days ago

DRTS
+1.13%
DRTSW
0.00%
Q1 Virtual Investor Summit: On-Demand Presentations Now Live

NEW YORK, NY / ACCESS Newswire / March 18, 2025 /The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors who missed the live sessions can now access company ...

ACCESS Newswire last month

VOXR

PYPD

GIFT
Sidoti Events, LLC's Virtual March Small-Cap Conference

NEW YORK CITY, NY / ACCESS Newswire / March 18, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March ...

ACCESS Newswire last month

MFIN

GNK

SGC
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) - - I

GlobeNewswire last month

DRTS
+1.13%
DRTSW
0.00%
March 2025 Penny Stocks To Consider For Growth

As the U.S. stock market grapples with economic uncertainties and fluctuating indices, investors are increasingly exploring diverse opportunities for growth. Penny stocks, often associated with smaller or newer companies, continue to capture interest due to their potential for significant returns at lower price points. Despite being considered a somewhat outdated term, these stocks can offer substantial growth prospects when backed by solid financials and strong fundamentals.

Simply Wall St. last month

DRTS
+1.13%
DRTSW
0.00%
WRAP
Alpha Tau to Participate in March Investor Conferences

JERUSALEM, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the following investor conferences in March 2025. Event:Investor Summit EventFormat:PresentationDate:March 11, 2025Time:12:00PM – 12:30PM ETLocation:Virtual Event:Oppenheimer 35th Annual Healthcare MedTech & Services ConferenceFormat:PresentationDat

GlobeNewswire last month

DRTS
+1.13%
DRTSW
0.00%
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the achievement of Medical Device Single Audit Program (MDSAP) certification for the company’s manufacturing facility in Jerusalem, as part of the Company’s commitment to quality, safety, and regulatory compliance while accelerating the global expansion of alpha-radiation cancer thera

GlobeNewswire last month

DRTS
+1.13%
DRTSW
0.00%
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

JERUSALEM, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today an approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining the combination of Alpha DaRT and first-line chemotherapy in 12 patients

GlobeNewswire 2 months ago

DRTS
+1.13%
DRTSW
0.00%
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of Alpha DaRT® - - Ad-hoc analyses of pancreatic cancer population subgroups suggest meaningful improvement in median overall survival (OS) for patients treated with Alpha DaRT after prior therapy, compared to previously published studies of alternative monotherapies, across all analyzed subgroups – - Investigational Device Exemption (IDE) received from the F

GlobeNewswire 2 months ago

DRTS
+1.13%
DRTSW
0.00%
US Penny Stocks To Consider In January 2025

As we step into January 2025, the U.S. stock market is experiencing a downturn with major indices like the S&P 500 and Nasdaq Composite sliding due to rising Treasury yields and mixed economic data. In this climate, investors often look for opportunities in less conventional areas such as penny stocks, which can offer growth potential at lower price points despite their historical reputation as high-risk investments. While the term "penny stock" may seem outdated, these smaller or newer...

Simply Wall St. 3 months ago

DRTS
+1.13%
DRTSW
0.00%
OSUR
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that an abstract entitled “Interim analysis of feasibility, safety, and tumor control in two first-in-human trials of a novel alpha-emitting radionuclide for pancreatic adenocarcinoma,” submitted by principal investigators involved in the Company’s Israeli pancreatic cancer trial, has

GlobeNewswire 4 months ago

DRTS
+1.13%
DRTSW
0.00%
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company’s Board of Directors (“Board”). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serv

GlobeNewswire 4 months ago

DRTS
+1.13%
DRTSW
0.00%
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestonesJERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 43rd Annual Healthcare Conference on Thursday, Janua

GlobeNewswire 4 months ago

DRTS
+1.13%
DRTSW
0.00%
Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium

JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the Ladenburg Oncology Innovators & Investors Symposium. Event:Ladenburg Oncology Innovators & Investors SymposiumFormat:Presentation and 1-on-1 MeetingsDate:December 12, 2024Time:11:00AM – 11:25AM ESTLocation:Virtual Please reach out to your Ladenb

GlobeNewswire 4 months ago

DRTS
+1.13%
DRTSW
0.00%
3 Promising Penny Stocks In The US With Market Caps Under $400M

As the U.S. stock market reaches record highs, with indices like the S&P 500 and Dow Jones posting their biggest monthly gains of 2024, investors are exploring opportunities beyond well-known large-cap stocks. Penny stocks, often representing smaller or newer companies, continue to intrigue investors despite their vintage name. This article will spotlight several penny stocks that stand out for their financial strength and potential for long-term success amidst current market conditions.

Simply Wall St. 4 months ago

BARK

BARK-WS

DRTS
+1.13%
Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha DaRT® for patients with recurrent glioblastoma multiforme (GBM) - - First patient treated in Recurrent Lung Cancer study in Israel, which will assess the safety and feasibility of delivering Alpha DaRT® sources into the lung using an endobronchial ultrasound procedure - - FDA approval of an Investigational Device Exemption (IDE) application to initiate

GlobeNewswire 5 months ago

DRTS
+1.13%
DRTSW
0.00%
Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference

JERUSALEM, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the Citi 2024 Global Healthcare Conference on December 3rd, 2024 and the Piper Sandler 36th Annual Healthcare Conference on December 5th, 2024. Event:Citi 2024 Global Healthcare ConferenceFormat:1-on-1 MeetingsDate:December 3, 2024Time:8:30AM –

GlobeNewswire 5 months ago

DRTS
+1.13%
DRTSW
0.00%
Discover Alpha Tau Medical And 2 Other US Penny Stocks

The U.S. stock market has recently experienced a rally, driven by strong earnings from major tech companies and a steady jobs report, which have bolstered investor confidence despite recent fluctuations. Amidst these broader market dynamics, the concept of penny stocks remains relevant for those seeking affordable entry points into potentially high-growth investments. These stocks often represent smaller or newer companies and can offer significant value when supported by robust financials...

Simply Wall St. 5 months ago

KRMD

DRTS
+1.13%
DRTSW
0.00%
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha DaRT®, announced today that it has been accepted into the prestigious Total Product Life Cycle (TPLC) Advisory Program (“TAP”) Pilot of the U.S. Food and Drug Administration (“FDA”), to accelerate market access to the Alpha DaRT for patients with recurrent glioblastoma multiforme (“GBM”). This acceptance fol

GlobeNewswire 5 months ago

DRTS
+1.13%
DRTSW
0.00%
Alpha Tau’s Alpha DaRT Advances Lung Cancer Treatment

Alpha Tau Medical Ltd (DRTS) has released an update. Alpha Tau Medical Ltd., a pioneer in alpha-radiation cancer therapy, has successfully treated its first patient with recurrent lung cancer using its breakthrough Alpha DaRT technology at Hadassah Medical Center in Jerusalem. The clinical trial, which allows for concurrent chemotherapy or immunotherapy, aims to assess the safety, feasibility, and efficacy of Alpha DaRT in treating tumors in the chest area. This development could potentially off

TipRanks 6 months ago

DRTS
+1.13%
DRTSW
0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alpha Tau Medical Ltd. (DRTSW)

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

Sidoti Events, LLC's Virtual March Small-Cap Conference

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

March 2025 Penny Stocks To Consider For Growth

Alpha Tau to Participate in March Investor Conferences

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

US Penny Stocks To Consider In January 2025

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium

3 Promising Penny Stocks In The US With Market Caps Under $400M

Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference

Discover Alpha Tau Medical And 2 Other US Penny Stocks

Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Alpha Tau’s Alpha DaRT Advances Lung Cancer Treatment